Skip to main content

Advertisement

Table 2 Patient characteristics

From: Oral mucositis associated with anti-EGFR therapy in colorectal cancer: single institutional retrospective cohort study

  Pmab group N = 32 Cmab group N = 43 P-value
Sex
 Male 23 (72%) 30 (70%) 1.00
Age (years) 65.7 (9.0) 63.1 (12.4) 0.33
Body weight (kg) 58.1 (10.0) 57.9 (9.0) 0.91
Body surface area (kg/m2) 1.62 (0.17) 1.60 (0.16) 0.59
Performance Status (ECOG)
 0 / 1 / 2 15 (47%) / 16 (50%) / 1 (3%) 27 (63%) / 15 (35%) / 1 (2%) 0.39
Diabetes mellitus 8 (25%) 6 (14%) 0.25
Smoking status
 Never / former / current 8 (25%) / 15 (47%) / 9 (28%) 17 (40%) / 16 (37%) / 10 (23%) 0.42
Serum albumin level (g/dl) 3.64 (0.66) 3.74 (0.36) 0.43
Primary origin of tumors
 Rectal / colon / other 9 (28%) / 22 (69%) / 1 (3%) 22 (51%) / 18 (42%) / 3 (7%) 0.07
 On the left side of the colon / on the right side of the colona 21 (66%) / 11 (34%) 33 (78%) / 10 (23%) 0.31
Line of treatment
 1st / 2nd / 3rd 25 (78%) / 6 (19%) / 1 (3%) 38 (88%) / 4 (9%) / 1 (2%) 0.47
Combined regimen
 FOLFOX / FOLFIRI / LV5FU 22 (69%) / 9 (28%) / 1 (3%) 38 (88%) / 4 (9%) / 1 (2%) 0.10
Concomitant bolus 5-FU
 Presence / absence 32 (100%) / 0 (0%) 41 (95%) / 2 (5%) 0.50
 Relative dose intensity in cycle 1 (%) 97.3 (7.8) 93.0 (21.6) 0.28
Cetuximab intervalb
 Weekly / biweekly - 13 (30%) / 30 (70%) -
  1. Data are expressed as mean (SD) and n (%).
  2. aOn the left side of the colon means descending colon, sigmoid colon, and rectum. On the right side of the colon means the cecum and ascending colon.
  3. bWeekly means cetuximab administered weekly; the initial dose was 400 mg/m2 and the maintenance dose was 250 mg/m2. Biweekly means a 500-mg/m2 dose of cetuximab administered every other week.